# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary Seacole (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI027-SYN-TD
- Date: 1877-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adwoa Fairweather-Kent, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review. **S**

## History of present illness

Mary Seacole returns two months after her annual wellness visit and six months after her first visit. Her home readings average 126/74 on amlodipine and losartan, with no dizziness on standing and only slight evening ankle swelling. She has had no falls. She walks 20 minutes most days with her cane, goes to tai chi twice a week and to the lunch club, and has lost 2 kg. Her knee pain is 3 out of 10. Her bone density scan showed osteopenia (lowest T-score -1.7 at the left femoral neck) with a 10-year hip fracture risk of 1.4%, below the level at which medicine is advised. Her mammogram, stool test and hepatitis C test were normal. She would like her vaccines today. **S**

| Element | Detail |
|---|---|
| Home readings | Average 126/74 mmHg |
| Falls | None |
| Knees | Pain 3 out of 10; walking 20 minutes most days |
| Screening | Osteopenia below the treatment threshold; mammogram, stool test and hepatitis C normal |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No dizziness on standing, chest pain or breathlessness; slight evening ankle swelling |
| Neurological | Negative | No headaches, weakness or numbness |
| Musculoskeletal | Positive | Knee pain 3 out of 10; no muscle aches on atorvastatin |

3 systems reviewed. **S**

## Current medications

- Diclofenac sodium 1% topical gel, 4 g rubbed into each painful knee up to four times a day **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Losartan 25 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76 kg; BMI 30.8 kg/m². All vital signs are synthetic.

Knee pain (0 to 10): 3; KOOS JR (0 worst to 100 best): 66.2. All results are synthetic.

## Change since baseline

- Knee pain (0 to 10): 6 at baseline, 3 at this visit **S**
- KOOS JR (0 worst to 100 best): 52.5 at baseline, 66.2 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**
- Influenza vaccine, high-dose **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/76 seated, 126/74 standing at three minutes, pulse 72; weight 76.0 kg |
| Cardiovascular | Regular rhythm; trace ankle edema |
| Musculoskeletal | No knee effusion; Timed Up and Go 12 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension** (I10). At target: 128/76 in the clinic and 126/74 at home, without an orthostatic drop. Potassium and creatinine were normal at the wellness visit. **S**
   - Continue amlodipine 5 mg, losartan 25 mg and atorvastatin 20 mg.
   - Metabolic panel and urine albumin in six months; lipids yearly.
2. **Knee osteoarthritis** (M17.0). Pain 3 out of 10; KOOS JR 66.2, up from 52.5. **S**
   - Continue tai chi, walking, the gel and her massage.
3. **Obesity, class 1** (E66.811). 2.6% weight loss so far; the goal is 5%. **S**
   - Continue the walking and food changes she has chosen.
4. **Fall risk** (Z91.81). No falls in six months; Timed Up and Go 12 seconds. Osteopenia below the treatment threshold. **S**
   - Calcium-rich foods and vitamin D from food and sunlight; bone density again in a few years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, large cuff, two readings) and at home; target below 130/80 mmHg | Every visit | Completed today | 128/76 mmHg; home average 126/74: at target |
| Examination | Orthostatic blood pressure (lying and standing) | Every visit | Completed today | No orthostatic drop |
| Examination | Weight and BMI (5% weight-loss goal for knee osteoarthritis) | Every visit | Completed today | 76.0 kg, BMI 30.8 (2.6% loss) |
| Examination | Cardiac auscultation and edema | Every visit | Completed today | Trace ankle edema |
| Laboratory | Sodium, potassium, creatinine and eGFR | Two to four weeks after starting or changing a diuretic or ARB; then every six months on these medicines | Up to date | Potassium 4.4 mmol/L and creatinine 0.98 mg/dL four weeks after losartan, at the wellness visit; next in six months |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin, then yearly | Up to date | LDL 82 mg/dL at the three-month review; next in a year |
| Laboratory | Urine albumin-to-creatinine ratio, hemoglobin A1c and TSH | At diagnosis, then yearly | Up to date | Normal six months ago; due in six months |
| Survey | Depression screen (PHQ-9) | Yearly | Up to date | PHQ-9 6 at the geriatric assessment; PHQ-2 1 at the wellness visit |
| Survey | Knee pain score (0 to 10) | Every visit | Completed today | 3 out of 10 |
| Survey | Knee function (KOOS JR) | Every visit | Completed today | KOOS JR 66.2 |
| Examination | Knee examination (range of motion, effusion, alignment, crepitus) | Every visit | Completed today | No effusion |
| Self-management | Exercise therapy, tai chi and self-management | Ongoing | Completed today | Tai chi twice a week; walks 20 minutes most days |
| Medication safety | NSAID safety (topical diclofenac; no oral NSAIDs) | Every visit | Completed today | Diclofenac gel only |
| Examination | STEADI assessment: Timed Up and Go, 30-second chair stand, 4-stage balance | At diagnosis of fall risk, then yearly or with a fall | Completed today | Timed Up and Go 12 seconds; no falls |
| Imaging | Bone density (DXA) and fracture risk | Women 65 and older; repeat by fracture risk | Completed today | Osteopenia, lowest T-score -1.7; 10-year hip fracture risk 1.4%, major osteoporotic fracture 8%: no medicine |
| Self-management | Her own remedies: interactions and how she uses them | Every visit | Completed today | Liquorice still paused; ginger tea and liniment |
| Self-management | Loneliness, costs and transport | Every visit | Completed today | Tai chi and lunch club; loneliness score improving; costs manageable |
| Self-management | Influenza and other vaccines | Yearly for influenza | Completed today | High-dose influenza vaccine, Tdap and zoster dose 2 today |

## Goal progress

- Blood pressure below 130/80 mmHg at home and in the clinic, without dizziness on standing. Outcome by 1877-09-14: 128/76 in the clinic and 126/74 at home on amlodipine and losartan, with no orthostatic drop. **S**
- Headaches gone. Outcome by 1877-04-13: No headaches since the second week of treatment. **S**
- Knee pain 3 or less out of 10 and walking 20 minutes a day with a cane. Outcome by 1877-09-14: Pain 3 out of 10; KOOS JR 52.5 to 66.2; walks 20 minutes most days. **S**
- Lose 5% of body weight (about 4 kg). Outcome by 1877-09-14: 78.0 to 76.0 kg (2.6%). **S**
- No falls. Outcome by 1877-09-14: No falls in six months; one near-fall during the sodium problem, without injury. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019), American College of Rheumatology and Arthritis Foundation (Arthritis Rheumatol 2020;72(2):220-233)
- STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026), Centers for Disease Control and Prevention
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American Heart Association and American College of Cardiology (Circulation 2019;139(25):e1082-e1143)
- Licorice Root (2026), National Center for Complementary and Integrative Health
- Ginger (2026), National Center for Complementary and Integrative Health
- CMID: Clinical Monitoring Intelligence Database, hypertension, osteoarthritis and osteoporosis monographs (2026), Aether Forge
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in three months; metabolic panel and urine albumin in six months. COVID-19 vaccine this autumn. Call for any fall, dizziness or sudden weakness, numbness or trouble speaking (call 999 at once). **S**

